Hormonal
GLP-1 receptor agonists (GLP-1RAs) significantly reduce HbA1c levels and body weight in patients with type 2 diabetes and obesity, with efficacy increasing from single agonists to dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists.
GLP-1 based medications (single, dual, and triple agonists) are highly effective for treating type 2 diabetes and obesity. They work by mimicking hormones that regulate blood sugar and appetite. Newer dual and triple agonists (like Tirzepatide and Retatrutide) show greater improvements in blood sugar and weight loss than older single-agonist drugs. Treatment is typically chronic, as stopping the medication often leads to weight regain. Options include weekly or daily injections, and some oral formulations are available for those who prefer to avoid needles. Consult a doctor to determine the best agent and dose for your specific health profile.
GLP-1RAs have demonstrated benefits in managing blood sugar levels and weight, cardiovascular disease prevention, and kidney health... These agents reduce HbA1c levels, facilitate weight loss, and exhibit cardiovascular protective effects... novel agents which are dual and triple hormonal agonists which represent the future direction of incretin-based therapy.
Why this rating
The review synthesizes data from multiple randomized controlled trials (RCTs) and phase 2/3 clinical trials, providing robust evidence for efficacy.
Source
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.102782
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →